(Q37345896)

19 August 2017

1 reference

title

Azathioprine in inflammatory bowel disease: improved molecular insights and resulting clinical implications (English)

1 reference

inflammatory bowel diseases

19 August 2017

main subject

0 references

0 references

2

Markus F Neurath

1 reference

19 August 2017

Imke Atreya

1

1 reference

19 August 2017

publication date

1 February 2008

1 reference

Expert Review of Gastroenterology & Hepatology

19 August 2017

published in

1 reference

19 August 2017

volume

2

1 reference

19 August 2017

issue

1

1 reference

19 August 2017

page(s)

23-34

1 reference

Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation?

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

CARD15/NOD2 mutations in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

The fundamental basis of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Guidelines for the management of inflammatory bowel disease in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Regulatory T cells: peace keepers in the gut.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

T cells of the human intestinal lamina propria are high producers of interleukin-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Insights in immunomodulatory therapies for ulcerative colitis and Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Randomised controlled trial of azathioprine withdrawal in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Azathioprine in inflammatory bowel disease, a safe alternative?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

From immunogenic mechanisms to novel therapeutic approaches in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Inflammatory bowel disease: clinical aspects and established and evolving therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Anti-interleukin-12 antibody for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Natalizumab for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

The George Hitchings and Gertrude Elion Lecture. The pharmacology of azathioprine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Structural effect of the anticancer agent 6-thioguanine on duplex DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Structure and dynamics of thioguanine-modified duplex DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Thiopurines, DNA damage, DNA repair and therapy-related cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Lymphocyte signalling: a coordinating role for Vav?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Vav proteins, adaptors and cell signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

GTPases and T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the vav proto-oncogene product

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

STATs and gene regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

MEK kinases are regulated by EGF and selectively interact with Rac/Cdc42

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Regulation of Bcl-xL: a little bit of this and a little bit of STAT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Regulation of cortical structure by the ezrin-radixin-moesin protein family

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Long-term effectiveness of azathioprine in IBD beyond 4 years: a European multicenter study in 1176 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Three novel thiopurine S-methyltransferase allelic variants (TPMT*20, *21, *22) - association with decreased enzyme function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

TPMT in the treatment of Crohn's disease with azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Mutation in the ITPA gene predicts intolerance to azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Glutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

6-thioguanine--efficacy and safety in chronic active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Pharmacological Monitoring of Azathioprine Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Thioguanine-nucleotides do not predict efficacy of tioguanine in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Blockade of interleukin 6 trans signaling suppresses T-cell resistanceagainst apoptosis in chronic intestinal inflammation: Evidence in Crohn diseaseand experimental colitis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

Sequential evaluation of thiopurine methyltransferase, inosine triphosphate pyrophosphatase, and HPRT1 genes polymorphisms to explain thiopurines' toxicity and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.23

21 January 2018

Identifiers

DOI

10.1586/17474124.2.1.23

1 reference

19 August 2017

1 reference